Key Points
- Director Richard Prins sold 7,973 Amphastar shares at an average price of $20.30, generating $161,851.90. His remaining stake fell 21.21% to 29,625 shares.
- Amphastar exceeded quarterly expectations, reporting $0.91 in EPS versus the $0.62 consensus estimate and revenue of $183.90 million, ahead of the $179.92 million forecast.
- Analysts remain cautious, with a consensus “Reduce” rating and a $22.00 target price; six analysts rate the stock Hold and two rate it Sell.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) Director Richard Prins sold 7,973 shares of the firm's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $20.30, for a total value of $161,851.90. Following the completion of the sale, the director directly owned 29,625 shares of the company's stock, valued at approximately $601,387.50. This represents a 21.21% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.
Amphastar Pharmaceuticals Stock Performance
AMPH opened at $19.98 on Thursday. Amphastar Pharmaceuticals, Inc. has a 52-week low of $16.65 and a 52-week high of $31.26. The company has a quick ratio of 1.71, a current ratio of 2.40 and a debt-to-equity ratio of 0.79. The company has a market cap of $849.95 million, a P/E ratio of 11.82, a price-to-earnings-growth ratio of 4.31 and a beta of 0.89. The firm's 50-day moving average price is $19.78 and its 200-day moving average price is $21.23.
Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.62 by $0.29. The firm had revenue of $183.90 million during the quarter, compared to analyst estimates of $179.92 million. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.98%. As a group, equities analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 2.25 EPS for the current fiscal year.
Hedge Funds Weigh In On Amphastar Pharmaceuticals
Several hedge funds and other institutional investors have recently bought and sold shares of AMPH. Dimensional Fund Advisors LP raised its position in Amphastar Pharmaceuticals by 12.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,027,947 shares of the company's stock worth $39,726,000 after buying an additional 228,262 shares during the last quarter. TD Asset Management Inc boosted its holdings in shares of Amphastar Pharmaceuticals by 1.6% in the 4th quarter. TD Asset Management Inc now owns 1,963,052 shares of the company's stock valued at $52,571,000 after acquiring an additional 31,160 shares during the last quarter. State Street Corp boosted its holdings in shares of Amphastar Pharmaceuticals by 2.1% in the 4th quarter. State Street Corp now owns 1,531,786 shares of the company's stock valued at $41,021,000 after acquiring an additional 31,044 shares during the last quarter. Fuller & Thaler Asset Management Inc. increased its stake in shares of Amphastar Pharmaceuticals by 3.0% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 1,394,463 shares of the company's stock worth $37,344,000 after acquiring an additional 40,536 shares during the period. Finally, Marshall Wace LLP increased its stake in shares of Amphastar Pharmaceuticals by 41.6% in the fourth quarter. Marshall Wace LLP now owns 1,237,284 shares of the company's stock worth $33,134,000 after acquiring an additional 363,216 shares during the period. Institutional investors and hedge funds own 65.09% of the company's stock.
Analysts Set New Price Targets
A number of research firms have issued reports on AMPH. Piper Sandler decreased their price target on shares of Amphastar Pharmaceuticals from $21.00 to $20.00 and set a "neutral" rating for the company in a report on Friday, August 7th. Wells Fargo & Company boosted their price objective on shares of Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the company an "equal weight" rating in a report on Friday, August 7th. Zacks Research raised Amphastar Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Tuesday, July 21st. Barclays reduced their target price on Amphastar Pharmaceuticals from $23.00 to $20.00 and set an "equal weight" rating for the company in a research note on Wednesday, June 3rd. Finally, Bank of America reaffirmed an "underperform" rating and set a $20.00 price target (down from $25.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, June 29th. Six equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Reduce" and a consensus target price of $22.00.
Check Out Our Latest Research Report on Amphastar Pharmaceuticals
About Amphastar Pharmaceuticals
(
Get Free Report)
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company's manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.
Amphastar's portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
